Abstract: A method for acquiring an indication of a preferred beam of a wireless communication device is disclosed. The method is performed in a network node of a cellular communication network. The network node is adapted to support a plurality of beams of a signal beam-forming scheme and to communicate with the wireless communication device using at least one beam of the plurality of beams. A message indicative of the beam power setting is transmitted to the wireless communication device. Measurement signals are also transmitted. A report indicative of the preferred beam is received from the wireless communication device. The preferred beam is determined by the wireless communication device based on the measurement signals and the beam power setting. Corresponding methods for the wireless communication device, as well as corresponding arrangements, network node, wireless communication device, cellular communication network, and computer program products are also disclosed.

Abstract: A peritoneal dialysis (“PD”) system includes a housing and a dialysis fluid pump housed by the housing. The dialysis fluid pump includes a reusable pump body that accepts PD fluid for pumping and a flush flow port. The PD system also includes a dialysis fluid heater for heating PD fluid, a container configured to accept and hold PD fluid, a condenser in fluid communication with the container, a chamber in fluid communication with the condenser and a flush flow line extending from the chamber to the flush flow port. The PD system further includes a control unit programmed to cause the dialysis fluid heater to heat PD fluid in the container to form steam or water vapor. The steam or water vapor is condensed in the condenser into distilled water collected in the chamber and provided from the chamber to the flush flow port via the flush flow line.

Abstract: There is provided mechanisms for OTA testing of an AAS of an EUT. A method is performed by a network node. The method includes obtaining definition of a test signal to be transmitted or received by the EUT in accordance with a time/frequency resource grid. The method includes applying first beamforming weights to first selected resource elements of the time/frequency resource grid that give first beam directions according to a first type of configuration for first OTA testing of the AAS. The method includes applying second beamforming weights to second selected resource elements of the time/frequency resource grid that give second beam directions according to a second type of configuration for second OTA testing of the AAS. The method includes initiating transmission or reception of the test signal over the AAS using the time/frequency resource grid.

Abstract: A substrate for a dual interface smartcard, comprising a contact pad module receiving portion; an auxiliary module receiving portion; and a conductor pattern. The conductor pattern includes an antenna coil having a first end and a second end; a first set of connectors arranged in the contact pad module and including a GND connector and a VCC connector for electrical connection with a VCC connector of the contact pad module; a second set of connectors arranged in the auxiliary module receiving portion and including a GND connector and a VCC connector; and leads connecting connectors in the first set with connectors in the second set. One of the GND connector and the VCC connector in the first set of connectors is conductively connected to one of the first end and the second end of the antenna coil.

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract: A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract: A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and arc designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract: Embodiments of the invention provide a zipper attached safety layer applied between a flexible mat and an edge pad of a trampoline. The safety layer moves with the flexible mat and prevents a user from accidently inserting an appendage into the suspension system (e.g., coiled springs) of the trampoline. Embodiments of the invention further relate to a trampoline comprising such a zippered safety layer and to a method of arranging the safety layer in a trampoline.

Abstract: A vehicle driveline system for a vehicle is provided. The system comprises a differential (110) having two output shafts (111,112) being connectable with respective wheel shafts, a primary electrical motor (121) being connected with a driving input (117) of the differential (110) via a first reduction gearing (130), said first reduction gearing (130) being connected to a secondary electrical motor (122) for adjusting the gear ratio of the first reduction gearing (130); whereby the secondary electrical motor (122) is connected to a clutch arrangement (150) configured to selectively lock the gear ratio of the first reduction gearing (130).

Abstract: A hydraulic system (10) for a vehicle is provided. The hydraulic system comprises a shifting mechanism (20) and a pump assembly (30) configured to provide pressurized fluid to said shifting mechanism (20), and an electrical motor (40). The movement of the shifting mechanism (20) controls a valve function which serves to open a connection from the pump assembly (30) to the electrical motor (40).

Abstract: Embodiments of the invention provide a zipper attached safety layer applied between a flexible mat and an edge pad of a trampoline. The safety layer moves with the flexible mat and prevents a user from accidently inserting an appendage into the suspension system (e.g., coiled springs) of the trampoline. Embodiments of the invention further relate to a trampoline comprising such a zippered safety layer and to a method of arranging the safety layer in a trampoline.

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract: A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).

Abstract: A method is provided for controlling the injection, by a reductant injector in an exhaust system for an internal combustion engine, of reductant for an exhaust aftertreatment unit of the exhaust system, for example a selective catalytic reduction (SCR) unit. The method includes determining a reductant injection debt in dependence on a reductant flow according to at least a first request being higher than a threshold of the reductant flow, and, at least partly in dependence on the reductant injection debt, controlling the reductant injector so as to inject a compensation flow.